Protagen AG Appoints New Board Members
News Oct 05, 2015
Protagen AG, the technology leader in the development of novel molecular diagnostic and companion diagnostic tests for autoimmune diseases, has elected Dr. Dirk Ehlers, CEO of Trumpf Medical in Puchheim, to the company‘s Supervisory Board. Simultaneously, Ulrich Kintzel, Senior Investment Manager of NRW.BANK in Düsseldorf, succeeded Dr. Aristotelis Nastos as representative of NRW.BANK, and Matthias Guth, was appointed by MIG AG in Munich, to follow Michael Motschmann in his board position.
Dr. Ehlers has served in executive positions at Eppendorf, Roche Diagnostics, Evotec, Fresenius Kabi and Olympus Diagnostics and has a proven track record in the Diagnostics Industry, with deep expertise in marketing and commercialization.
According to Dr. Ehlers, “Protagen offers an outstanding technology that addresses the current needs of the autoimmune diagnostics industry, which remains many years behind oncology diagnostics in terms of new molecular content, time to market and therapy support. The Protagen technology is able to deliver novel, validated biomarkers and significantly reduce the time to market. I look forward to supporting the efforts of the company in translating its significant potential into a commercial success story.”
Stefan Müllner, CEO of Protagen, added: “In order to become the leading provider of Dx and CDx for autoimmune therapy, and to foster the potential for strategic collaborations and partnerships, it is imperative that we have meaningful insight into the strategies and processes of the global diagnostic leaders. The profound expertise Dr. Ehlers will bring to this role will provide us with valuable guidance, and will help us to effectively expand our business within the growing and demanding autoimmune Dx field. Together with the expertise of Wolfgang Kintzel, executive manager at AMAXA and CEVEC before joining NRW.BANK, and Matthias Guth, with nearly two decades of experience as investment manager in the biotech industry, Protagen is backed by a Supervisory Board of distinguished industrial experts with synergistic expertise.”
New Blood and Urine Tests Indicate Autism in ChildrenNews
New tests, developed by researchers at the University of Warwick, could lead to earlier diagnosis of the condition.READ MORE
Specific Set of Nerve Cells Controls Seizures’ Spread Through BrainNews
This discovery could lead to new and better treatments for epilepsy.READ MORE
From Human Biopsy to Complex Gut Physiology on a ChipNews
Organ Chip technology using donor-derived human intestinal cells offers advantages over organoids and creates new opportunities for personalized medicine.READ MORE